About Nathanael Lentz
Form D filings for Curavit Clinical Research from 2022 to 2024 list Nathanael Lentz as director.
Nathanael Lentz first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Nathanael Lentz in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Nathanael Lentz works with at each company, as listed on that company's latest Form D.
Curavit Clinical Research Corp · Form D/A, Sep 5, 2024
JK
Jackie Kent
Director
RL
Rich Lester
Director
JM
Joel Morse
Chief Executive Officer and director
DH
David Hanaman
Director